132 related articles for article (PubMed ID: 17476677)
21. Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent?
Cuffari C; Lichtenstein GR
Gastroenterology; 2003 Jun; 124(7):1988-90. PubMed ID: 12806638
[No Abstract] [Full Text] [Related]
22. Infliximab for the treatment of fistulas in patients with Crohn's disease.
Present DH; Rutgeerts P; Targan S; Hanauer SB; Mayer L; van Hogezand RA; Podolsky DK; Sands BE; Braakman T; DeWoody KL; Schaible TF; van Deventer SJ
N Engl J Med; 1999 May; 340(18):1398-405. PubMed ID: 10228190
[TBL] [Abstract][Full Text] [Related]
23. Psoriasis induced by infliximab in a patient suffering from Crohn's disease.
Manni E; Barachini P
Int J Immunopathol Pharmacol; 2009; 22(3):841-4. PubMed ID: 19822070
[TBL] [Abstract][Full Text] [Related]
24. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
Heidemann J; Kucharzik T
Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
[No Abstract] [Full Text] [Related]
25. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
Papadakis KA; Shaye OA; Vasiliauskas EA; Ippoliti A; Dubinsky MC; Birt J; Paavola J; Lee SK; Price J; Targan SR; Abreu MT
Am J Gastroenterol; 2005 Jan; 100(1):75-9. PubMed ID: 15654784
[TBL] [Abstract][Full Text] [Related]
26. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
27. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease.
Sorrentino D; Terrosu G; Avellini C; Maiero S
Arch Intern Med; 2007 Sep; 167(16):1804-7. PubMed ID: 17846401
[No Abstract] [Full Text] [Related]
28. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
29. Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis.
Calderón R; Estrada S; Ramírez de la Piscina P; Salvador M; Zabaleta S; Enciso C; Delgado E; García-Campos F
Rev Esp Enferm Dig; 2010 Feb; 102(2):145-6. PubMed ID: 20361852
[No Abstract] [Full Text] [Related]
30. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease.
Miheller P; Muzes G; Zagoni T; Toth M; Racz K; Tulassay Z
Dig Dis; 2006; 24(1-2):201-6. PubMed ID: 16699279
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of psychosis with infliximab in a patient with Crohn's disease.
Reimer J; Fink T; Bläker M; Schäfer I; Otte C
Schizophr Res; 2009 Apr; 109(1-3):194-5. PubMed ID: 19223267
[No Abstract] [Full Text] [Related]
32. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab.
Ogawa K; Matsumoto T; Esaki M; Torisu T; Iida M
J Crohns Colitis; 2012 Jun; 6(5):529-35. PubMed ID: 22398057
[TBL] [Abstract][Full Text] [Related]
33. Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease.
Kupcová V; Turecký L; Detková Z; Príkazská M; Keleová A
Physiol Res; 2003; 52(1):89-93. PubMed ID: 12625812
[TBL] [Abstract][Full Text] [Related]
34. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy.
Schmidt C; Giese T; Hermann E; Zeuzem S; Meuer SC; Stallmach A
Inflamm Bowel Dis; 2007 Jan; 13(1):65-70. PubMed ID: 17206641
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
Martín-de-Carpi J; Pociello N; Varea V
J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
[TBL] [Abstract][Full Text] [Related]
37. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
38. [Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
MMW Fortschr Med; 2008 Dec; 150(51-52):54-5. PubMed ID: 19156959
[No Abstract] [Full Text] [Related]
39. Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: the first case in the literature.
Sisman G; Erzin Y; Bal K
J Crohns Colitis; 2013 Oct; 7(9):e397-8. PubMed ID: 23583098
[No Abstract] [Full Text] [Related]
40. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
